Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is characterized by the
accumulation of lipids in the liver (steatosis). In predisposed individuals, liver steatosis can …

INTRODUCTION High-density lipoprotein (HDL) participates in cholesterol homeostasis and
may also have anti-inflammatory or anti-microbial roles through its interaction with numerous …

Background Nonalcoholic fatty liver disease (NAFLD) is increasingly identified in patients
with inflammatory bowel disease (IBD), but there are few systematic reviews and meta …

Background Conjugated linoleic acid (CLA) is an effective supplement for reducing fat mass,
but its effect on hepatic steatosis remains controversial. Objective This study aims to …

Background: The pathogenesis of MASLD (metabolic dysfunction-associated steatotic liver
disease) is driven by environmental, genetic, metabolic, immune, and inflammatory factors …

Background & Aims At least 20%–30% of patients with intestinal failure receiving long-term
parenteral nutrition will develop intestinal failure–associated liver disease (IFALD), for which …

Background The reported prevalence of nonalcoholic fatty liver disease (NAFLD) in patients
with inflammatory bowel disease (IBD) is 32%. We assessed the influence of NAFLD on IBD …

Introduction Massive intestinal loss resulting in short bowel syndrome has been linked to
intestinal failure associated liver disease. Efforts to elucidate the driving force behind the …

Background Massive small bowel resection (SBR) is associated with liver injury and fibrosis.
Efforts to elucidate the driving force behind hepatic injury have identified multiple factors …

Background: Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's
disease (CD), can affect the hepatobiliary system and pancreas, substantially impacting the …